New Three-Drug cocktail targets Hard-to-Treat lymphoma
Disease control
Ongoing
This early-phase study tests a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in 22 patients with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and see how well the body tolerates the c…
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Jun 26, 2026 15:12 UTC